

NCT ID	NCT05328908
Title	A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2022-04-14
Location	Arkansas, United States California, United States Connecticut, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Massachusetts, United States Michigan, United States Minnesota, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Canada Chile China Czechia France Germany Italy Japan Korea, Republic of Netherlands Poland Puerto Rico Singapore Spain Sweden Switzerland Taiwan
IO -centered	No
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Nivolumab-relatlimab FDC, Regorafenib, TAS-102, Lonsurf, Opdivo, Stivarga

NCT ID	NCT05223673
Title	Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2022-02-04
Location	Michigan, United States Ohio, United States Belgium Denmark Finland Japan

IO -centered	No
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Futuximab/modotuximab, Trifluridine/Tipiracil

NCT ID	NCT05198934
Title	Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)
Phase	Phase 3
Date Added	2022-01-20
Location	Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States North Carolina, United States Ohio, United States Tennessee, United States Texas, United States Australia France Germany Greece Italy Japan Korea, Republic of Mexico Spain Taiwan United Kingdom

IO -centered	No
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	

NCT ID	NCT05141721
Title	A Study of a Personalized Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer
Phase	Phase 2, Phase 3
Date Added	2021-12-02
Location	Alabama, United States Arizona, United States Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Maryland, United States Michigan, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Wisconsin, United States

IO -centered	No
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Atezolizumab, Bevacizumab, Fluoropyrimidine, GRT-C901, GRT-R902, Ipilimumab, oxaliplatin

NCT ID	NCT04793958
Title	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
Phase	Phase 3
Date Added	2021-03-11
Location	Alabama, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Iowa, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States North Carolina, United States Oklahoma, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Austria Belgium Canada China Czechia Denmark Finland France Germany Greece Hong Kong Ireland Italy Korea, Republic of Malaysia Mexico Netherlands Poland Portugal Puerto Rico Singapore Spain Taiwan Thailand United Kingdom

IO -centered	No
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849

NCT ID	NCT04776148
Title	Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)
Phase	Phase 3
Date Added	2021-03-01
Location	California, United States Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canada China Denmark Germany Israel Japan Korea, Republic of Russian Federation Spain Taiwan Turkey United Kingdom

IO -centered	No
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil)

NCT ID	NCT04607421
Title	A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
Phase	Phase 3
Date Added	2020-10-29

Location	Arizona, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Louisiana, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States Washington, United States Wisconsin, United States Argentina Australia Belgium Brazil Bulgaria Canada China Czechia Denmark Finland Germany India Italy Japan Korea, Republic of Mexico Netherlands New Zealand Norway Poland Russian Federation Slovakia South Africa Spain Sweden Taiwan Ukraine United Kingdom
IO -centered	No
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	5-FU, Bevacizumab, capecitabine, cetuximab, encorafenib, Irinotecan, Leucovorin, oxaliplatin
NCT ID	NCT04607668
Title	Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Phase	Phase 3
Date Added	2020-10-29

Location	Arizona, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Massachusetts, United States Minnesota, United States Nevada, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Virginia, United States China Hungary Italy Poland Spain Ukraine United Kingdom
IO -centered	No
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Placebo, Trilaciclib
NCT ID	NCT03084471
Title	An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
Phase	Phase 3
Date Added	2017-03-21
Location	California, United States District of Columbia, United States Illinois, United States Nebraska, United States New Jersey, United States New York, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Canada France Germany Italy Korea, Republic of Netherlands United Kingdom
IO -centered	No
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
NCT ID	NCT02928224
Title	Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Phase	Phase 3
Date Added	2016-10-10

Location	Arizona, United States California, United States Colorado, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Iowa, United States Kansas, United States Louisiana, United States Maryland, United States Massachusetts, United States Minnesota, United States Missouri, United States New Jersey, United States New York, United States Ohio, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Argentina Australia Austria Belgium Brazil Canada Chile Czechia Denmark France Germany Hungary Israel Italy Japan Korea, Republic of Mexico Netherlands Norway Poland Russian Federation Spain Taiwan Turkey Ukraine United Kingdom
IO -centered	No
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	5-Fluorouracil, Binimetinib, cetuximab, encorafenib, Folinic acid, Irinotecan